continu
threat
respiratori
virus
public
health
exemplifi
global
impact
sarscov
outbreak
occurr
sinc
confirm
human
case
avian
influenza
mani
countri
particularli
across
asia
influenza
pandem
recent
emerg
arab
peninsula
novel
coronaviru
respons
middl
east
respiratori
syndrom
merscov
new
strain
avian
influenza
jump
human
china
underscor
need
continu
work
direct
agre
sarscov
infect
respiratori
tract
also
affect
organ
system
sever
report
demonstr
infect
hematopoiet
cell
howev
mechan
sarscov
enter
immun
cell
express
sarscov
receptor
angiotensinconvert
enzym
remain
poorli
understood
ctype
lectin
receptor
liverlymph
nodespecif
intercellular
adhes
integrin
lsign
dendrit
cell
specif
intercellular
adhes
molecul
nonintegrin
dcsign
well
antibodymedi
infect
may
provid
sarscov
opportun
modifi
tropism
lack
effect
antivir
strategi
control
coronavirus
infect
vaccin
still
regard
major
option
prevent
resurg
sar
relat
diseas
previous
show
sarscov
vaccin
candid
base
recombin
fulllength
sarscov
spikeprotein
trimer
trigger
infect
human
b
cell
line
despit
elicit
vivo
neutral
protect
immun
respons
rodent
recent
demonstr
antispik
antibodi
potenti
infect
monocyt
lymphoid
immun
cell
line
sarscovpp
also
replicationcompet
sarscoronaviru
thu
provid
evid
novel
versatil
mechan
sarscov
enter
target
cell
express
convent
viru
receptor
otherwis
refractori
viru
infect
pathway
may
implic
understand
tropism
pathogenesi
viru
therefor
investig
molecular
cellular
mechan
underli
ade
sarscov
infect
monitor
suscept
human
bulk
primari
immun
cell
ie
peripher
blood
mononuclear
cell
establish
occurr
ade
sarscovpp
infect
differ
circul
immun
cell
type
among
monocyt
lineag
cell
primari
target
addit
monocyt
human
macrophag
also
infect
sarscov
presenc
antispik
antibodi
ademedi
infect
macrophag
howev
support
product
replic
viru
final
provid
evid
intracellular
signal
motif
igg
bind
motif
key
molecular
determin
trigger
ade
sarscovpp
find
conclus
demonstr
antispik
serum
promot
intern
sarscov
human
macrophag
previou
observ
reveal
human
monocyt
cell
line
suscept
ade
infect
investig
occurr
ade
infect
primari
human
macrophag
vitro
firstli
take
advantag
sarscovpp
safe
use
mimic
viral
entri
process
found
sarscovpp
opson
dilut
antispik
serum
readili
infect
primari
human
macrophag
determin
immunofluoresc
stain
firefli
luciferas
hour
post
infect
hpi
contrast
cell
expos
sarscovpp
opson
control
serum
show
posit
stain
luciferas
report
protein
figur
experi
extend
previou
observ
indic
antispik
antibodi
facilit
infect
sarscovpp
human
macrophag
next
test
whether
alter
tropism
also
display
replicationcompet
sarscov
human
macrophag
infect
multipl
infect
moi
dilut
antispik
control
immun
serum
infect
pattern
examin
immunofluoresc
stain
sarscov
nucleocapsid
protein
realtim
quantit
pcr
measur
viral
rna
posit
immunofluoresc
signal
detect
hpi
sarscov
opson
control
antispik
serum
figur
interestingli
wherea
presenc
control
serum
led
modest
infect
sarscov
cell
increas
percentag
posit
cell
note
presenc
antispik
serum
two
three
donor
figur
enhanc
infect
pattern
parallel
number
viral
gene
copi
measur
figur
thu
compar
inoculum
contain
control
serum
increas
detect
posit
neg
strand
viral
gene
macrophag
infect
presenc
antispik
serum
pronounc
hpi
rapid
declin
viral
rna
hpi
condit
chang
detect
later
time
point
figur
howev
note
primer
set
use
nucleocapsid
gene
could
also
detect
neg
strand
viral
genom
rna
could
distinguish
subgenom
materi
addit
measur
realtim
quantit
pcr
copi
viral
nucleocapsid
gene
cultur
supernat
determin
releas
sarscov
particl
infect
macrophag
copi
number
viral
rna
howev
remain
unchang
select
time
point
cours
experi
less
regardless
whether
macrophag
infect
presenc
either
control
antispik
serum
data
shown
previous
demonstr
mous
antispik
serum
could
trigger
infect
raji
cell
context
ade
antibodi
viral
protein
consid
major
player
enhanc
see
review
elimin
possibl
particip
solubl
factor
ade
sar
section
investig
capabl
antispik
antibodi
alon
enhanc
infect
immun
cell
purifi
igg
protein
gsepharos
chromatographi
mous
antispik
control
serum
use
serial
dilut
purifi
portion
form
immun
complex
sarscovpp
infect
raji
cell
result
show
purifi
igg
mous
antispik
serum
trigger
infect
raji
cell
pronounc
increas
immunoglobulin
concentr
figur
flowthrough
ft
serum
dilut
appropri
factor
compar
final
igg
concentr
use
elicit
detect
infect
concentr
data
shown
signific
differ
ade
infect
purifi
mous
antispik
igg
flowthrough
observ
concentr
margin
differ
observ
expect
neither
purifi
igg
figur
flowthrough
mous
control
serum
trigger
signific
ade
infect
concentr
recent
work
reveal
predomin
role
human
mediat
ade
sarscov
gain
insight
underli
molecular
mechan
investig
involv
differ
domain
mediat
ade
end
produc
seri
truncat
construct
carri
ectodomain
transmembran
domain
chimer
construct
ectodomain
one
receptor
transmembran
endodomain
anoth
figur
verifi
express
construct
cell
flow
cytometri
use
specif
monoclon
antibodi
clone
bind
second
iglik
domain
note
fc
bind
portion
group
similar
among
also
harbor
ident
extracellular
structur
find
indic
construct
exhibit
detect
express
dark
grey
cell
comparison
isotyp
control
light
grey
figur
test
abil
variou
construct
bind
purifi
antispik
iggsarscovpp
immun
complex
observ
transfect
abl
bind
immun
complex
figur
final
investig
whether
differ
suscept
sarscovpp
ade
infect
confer
differ
construct
immun
complex
form
purifi
mous
antispik
igg
concentr
highest
infect
level
observ
raji
cell
sarscovpp
ad
cell
four
transfect
express
wildtyp
form
cf
vs
vs
correspond
construct
respect
infect
figur
prone
infect
cf
construct
endodomaintrunc
construct
correspond
construct
respect
suscept
ade
infect
indic
bind
antispik
iggsarscovpp
immun
complex
suffici
mediat
entri
signalingcompet
endodomain
requir
howev
chimer
construct
abl
sustain
ade
infect
suggest
domain
swap
may
partial
interf
signal
transduct
thu
chimera
ectodomain
endomain
ectodomain
endomain
exhibit
statist
signific
ade
infect
figur
explain
differ
surfac
express
bind
opson
pseudoparticl
viz
construct
show
robust
ade
despit
one
lowest
bind
abil
immunecomplex
possibl
immun
respons
pathogen
may
also
deleteri
effect
host
homeostasi
focu
sever
studi
exampl
hyperinduct
cytokin
follow
avian
influenza
infect
implic
sever
diseas
infect
cell
ade
known
occur
sever
viral
diseas
demonstr
antispik
antibodi
potenti
infect
human
primari
immun
cell
sarscovpp
replicationcompet
sarscoronaviru
although
unambigu
obtain
evid
ongo
infect
eg
de
novo
synthesi
structur
viral
protein
n
adeinfect
macrophag
support
product
replic
sarscov
initi
viral
gene
transcript
viral
protein
synthesi
replic
process
stall
ultim
end
abort
viral
cycl
without
detect
releas
progeni
viru
abort
replic
sarscov
macrophag
alreadi
document
varianc
previou
report
macrophag
infect
sarscov
absenc
immuneserum
moi
observ
much
lower
infect
rate
one
possibl
discrep
may
due
differ
time
sampl
hour
studi
versu
hour
cheung
studi
protocol
use
vitro
differenti
viz
macrophag
differenti
presenc
fetal
calf
serum
studi
autolog
plasma
remov
two
day
prior
infect
ref
lead
differ
infect
cell
observ
studi
altern
also
consid
readout
pseudoparticl
experi
express
luciferas
report
gene
control
hiv
backbon
may
lead
higher
level
protein
express
compar
abort
replic
follow
sarscov
infect
macrophag
thu
differ
may
part
due
inabl
detect
low
amount
spike
protein
immunofluoresc
differ
sensit
two
method
note
antispik
mediat
entri
specif
spikepseudotyp
particl
shown
figur
clinic
observ
report
poor
diseas
outcom
earli
seroconvert
sar
patient
would
interest
test
sar
patient
sera
collect
differ
timepoint
sar
onset
howev
unabl
thu
far
conduct
conclus
assay
well
character
serum
librari
moreov
cogniz
possibl
ade
may
occur
within
narrow
window
cours
infect
subset
infect
patient
altern
possibl
intern
macrophag
may
fact
repres
addit
mechan
control
viral
spread
requir
investig
gener
studi
aim
better
understand
antibodydepend
enhanc
viral
infect
focus
either
identifi
immun
receptor
andor
serum
compon
allow
penetr
pathogen
target
cell
also
known
extrins
ade
outcom
respons
target
cell
downstream
ade
infect
intrins
ade
previou
result
demonstr
lesser
extent
trigger
infect
sarscovpp
presenc
antispik
serum
although
would
desir
perform
block
experi
also
macrophag
coexpress
cell
would
caus
block
antibodi
bind
target
via
fab
portion
also
via
fc
portion
make
unavail
interact
opson
pseudoparticl
consequ
would
prevent
unambigu
interpret
result
therefor
investig
molecularsign
requir
underli
infect
sarscov
assess
rel
contribut
extracellular
versu
transmembran
intracellular
domain
receptor
ii
famili
member
mediat
ade
infect
extracellular
iggbind
domain
human
close
relat
homolog
amino
acid
level
nonetheless
receptor
distinct
abil
affin
bind
immunoglobulin
moreov
carri
immunoreceptor
tyrosinebas
activ
motif
itam
wherea
carri
immunoreceptor
tyrosinebas
inhibitori
motif
itim
confer
igg
receptor
differ
effector
properti
altogeth
result
demonstr
bind
sarscovpp
cell
via
extracellular
domain
suffici
trigger
ade
infect
entri
requir
intact
intracellular
domain
inde
spite
roughli
similar
express
level
cell
surfac
compar
wild
type
mutat
receptor
truncat
intracellular
domain
becam
unabl
trigger
ade
infect
retain
signific
level
ligandbind
abil
result
obtain
chimer
construct
whole
intracellular
domain
swap
lend
support
interpret
note
transmembran
intracellular
domain
appear
impart
suscept
infect
parent
thu
wildtyp
elicit
greater
ade
graft
cytoplasm
portion
reduc
suscept
ade
chimera
extracellular
domain
level
compar
observ
truncat
mutant
howev
relationship
intern
immun
complex
ade
infect
sarscov
via
appear
complex
process
thu
shown
mediat
intern
immun
complex
faster
rate
wherea
found
ade
infect
via
promin
recent
involv
downstream
signal
trigger
activ
evalu
respect
ade
dengu
viru
infect
thu
abrog
signal
compet
associ
signific
impair
phagocytosi
signalingincompet
becom
unabl
trigger
ade
dengu
viru
convers
discern
effect
dengu
viru
immun
complex
infect
observ
wild
type
signal
incompet
find
point
fundament
differ
respect
immuneenhanc
capabl
suggest
differ
mechan
dengu
viru
immun
complex
intern
may
oper
altogeth
result
demonstr
presenc
vaccineelicit
antivir
antibodi
sarscov
display
alter
tropism
toward
primari
human
immun
cell
express
convent
viru
receptor
otherwis
refractori
viru
number
sar
vaccin
candid
test
experiment
anim
model
mani
base
viral
spike
glycoprotein
previous
identifi
immunogen
antigen
induc
neutral
protect
antibodi
note
vaccin
anim
coronavirus
also
gener
develop
proven
difficult
due
immun
enhanc
diseas
vaccin
recipi
despit
fact
altern
infect
pathway
appear
limit
impact
remain
interest
appreci
cost
antibodymedi
sarscov
infect
function
target
cell
order
broad
understand
tropism
pathogenesi
viru
evalu
potenti
pitfal
associ
immun
human
coronavirus
aspect
gain
relev
emerg
merscov
indic
avail
vaccin
target
group
virus
demonstr
abil
jump
speci
one
option
avail
prevent
spread
infect
caus
sever
diseas
high
mortal
human
follow
cell
line
use
studi
obtain
american
type
cultur
collect
atcc
manassa
va
usa
human
kidney
epitheli
cell
raji
burkitt
lymphomab
lymphoblast
burkitt
lymphomab
lymphoblast
lack
express
cell
cultur
dmem
supplement
heatinactiv
fetal
bovin
serum
fb
mgl
penicillin
mgl
streptomycin
wherea
hematopoiet
cell
grown
supplement
heatinactiv
fb
nonessenti
aminoacid
mm
lglutamin
mm
sodium
pyruv
mgl
penicillin
mgl
streptomycin
invitrogen
life
technolog
carlsbad
ca
usa
cell
maintain
humidifi
atmospher
suppli
research
protocol
approv
institut
review
board
univers
hong
konghospit
author
hong
kong
west
cluster
blood
sampl
healthi
donor
obtain
hong
kong
red
cross
blood
transfus
servic
human
blood
cell
isol
buffi
coat
monocytederiv
macrophag
gener
vitro
use
modifi
protocol
previous
describ
briefli
mononuclear
cell
isol
ficollpaqu
densiti
gradient
pharmacia
biotech
uppsala
sweden
remov
erythrocyt
granulocyt
cell
debri
monocyt
enrich
plastic
adher
harvest
seed
cellsml
tissu
cultur
plate
allow
differenti
day
presenc
autolog
human
plasma
fetal
calf
serum
use
puriti
macrophag
consist
ascertain
immunofluoresc
stain
human
lysosom
glycoprotein
highli
express
macrophag
monocyt
balbc
mice
immun
recombin
sarscov
spike
protein
adjuv
alum
previous
describ
salineinject
mice
serv
control
serum
collect
day
postimmun
heatinactiv
min
store
subsequ
use
protocol
produc
sarscov
pseudotyp
lentivir
particl
express
luciferas
report
gene
sarscovpp
describ
elsewher
follow
purif
step
sucros
cushion
concentr
viral
particl
titrat
elisa
lentivirusassoci
protein
accord
manufactur
instruct
cell
biolab
inc
san
diego
ca
usa
store
use
ade
assay
heatinactiv
mous
antispik
control
serum
incub
hr
sarscovpp
inoculum
deposit
cell
infect
proceed
hr
follow
repeat
wash
cell
incub
addit
hour
fix
paraformaldehyd
sigmaaldrich
inc
st
loui
mo
usa
immunofluoresc
microscopi
laboratori
procedur
involv
replicationcompet
virus
perform
biosafeti
contain
state
key
laboratori
emerg
infecti
diseas
univers
hong
kong
sarscov
strain
use
clinic
isol
cultur
fetal
rhesu
atcc
code
cell
ade
assay
heatinactiv
mous
antispik
control
serum
incub
h
sarscov
human
monocytederiv
macrophag
infect
moi
min
repeat
wash
cell
cultur
fresh
medium
time
supplement
fb
indic
time
point
hour
post
infect
pi
eventu
either
fix
paraformaldehyd
sigmaaldrich
inc
immunofluoresc
microscopi
resuspend
lysi
buffer
rlt
buffer
rneasi
rna
mini
kit
qiagen
germantown
md
usa
realtim
quantit
rtpcr
sampl
cell
cultur
supernat
harvest
differ
hpi
also
mix
rlt
buffer
process
rtpcr
infect
replicationcompet
sarscov
determin
indirect
immunofluoresc
mous
monoclon
antibodi
direct
sarscov
nucleocapsid
protein
clone
gift
dr
kwokhung
chan
depart
clinic
microbiolog
queen
mari
hospit
hong
kong
dilut
stain
reveal
isothiocyan
tritc
conjug
goat
antimous
antibodi
invitrogen
life
technolog
axioobserv
microscop
carl
zeiss
inc
thornwood
new
york
usa
pictur
taken
randomli
chosen
field
magnif
acquir
axiocam
mrm
camera
analyz
metamorph
softwar
molecular
devic
sunnyval
ca
usa
infect
determin
percentag
cell
express
viral
antigen
similar
stain
procedur
employ
assess
infect
sarscovpp
except
use
direct
immunofluoresc
fluorescein
isothiocyan
fitc
conjug
goat
monoclon
antibodi
specif
firefli
luciferas
rockland
gilbertsvil
pa
usa
dilut
rna
extract
rneasi
rna
mini
kit
qiagen
accord
manufactur
recommend
concentr
puriti
rna
measur
standard
optic
method
revers
transcript
perform
total
rna
superscript
iii
revers
transcriptas
specifi
manufactur
invitrogen
life
technolog
quantif
sarscov
gene
copi
cdna
gener
separ
reaction
presenc
either
forward
revers
primer
specif
nucleocapsid
gene
tabl
amplifi
neg
posit
strand
viral
rna
respect
assay
allow
distinguish
signal
gener
entri
input
viru
downstream
event
reflect
activ
replic
process
specif
primer
tabl
taqman
minor
groov
binder
probe
use
detect
sarscov
nucleocapsid
gene
previous
describ
howev
note
primer
set
use
nucleocapsid
gene
could
also
detect
neg
strand
viral
genom
rna
could
distinguish
subgenom
materi
qpcr
assay
carri
final
volum
fluoresc
signal
detect
lightcycl
roch
appli
scienc
mannheim
germani
program
follow
min
follow
cycl
sec
sec
sec
result
express
number
target
copi
per
copi
rrna
gene
use
normal
result
ensur
consist
qpcr
measur
time
period
studi
batch
primer
probe
employ
qpcr
result
consid
valid
effici
standard
curv
valu
greater
igg
purifi
immun
control
mice
use
protein
gsepharos
ge
healthcar
littl
chalfont
unit
kingdom
accord
manufactur
recommend
puriti
igg
fraction
check
silver
stain
follow
gel
electrophoresi
concentr
antispik
igg
determin
elisa
strategi
produc
plasmid
wildtyp
human
igg
receptor
consist
replac
enhanc
green
fluoresc
protein
egfp
gene
bicistron
vector
pchmwsegfpireshygromycin
kind
gift
dr
rik
gijsber
zeger
debys
katholiek
universiteit
leuven
belgium
code
sequenc
isoform
genbank
access
genbank
access
flank
bglii
sali
site
describ
elsewher
synthet
sequenc
geneart
regensburg
germani
insert
origin
transfer
plasmid
yield
wildtyp
construct
construct
swap
intracellular
domain
obtain
rtpcr
amplif
desir
sequenc
polyclon
raji
cdna
correspond
region
construct
wildtyp
construct
subsequ
use
gener
truncat
chimer
form
standard
techniqu
see
figur
schemat
represent
mutant
test
plasmid
sequenc
centr
genom
scienc
univers
hong
kong
cell
line
gener
transduct
monoclon
cell
vesicular
stomat
viru
vsv
g
pseudotyp
lentivir
particl
bear
specifi
transgen
previous
describ
day
postinfect
cell
surfac
express
monitor
flow
cytometri
cell
subsequ
cultur
select
medium
contain
hygromycin
invitrogen
life
technolog
appropri
final
sever
monoclon
cell
line
construct
isol
express
transgen
confirm
flow
cytometri
express
evalu
flow
cytometri
describ
follow
mous
mab
use
bd
pharmingen
frankin
lake
nj
usa
isotyp
control
biolegend
san
diego
ca
usa
cell
wash
primari
antibodi
bind
reveal
stain
ice
min
fitcconjug
goat
antimous
antibodi
jackson
immunoresearch
west
grove
pa
usa
data
collect
least
singlet
live
cell
lsrii
flow
cytomet
bd
bioscienc
san
jose
ca
usa
analyz
use
flowjo
softwar
treestar
ashland
usa
sarscovppigg
immun
complex
obtain
incub
sarscovpp
either
purifi
mous
antispik
control
igg
hr
mixtur
quickli
chill
ice
min
ad
cell
cellswel
previous
stain
fixabl
viabil
dye
efluor
ebiosci
san
diego
ca
usa
follow
hr
incub
ice
cell
wash
twice
cold
pb
fix
paraformaldehyd
min
ice
immun
complex
bind
reveal
stain
fitcconjug
goat
antimous
f
ab
jackson
immunoresearch
min
data
collect
analys
describ
result
shown
mean
sem
indic
number
observ
statist
differ
group
determin
unpair
student
ttest
signific
level
angiotensinconvert
ade
antibodydepend
enhanc
dcsign
dendrit
cell
specif
intercellular
adhes
molecul
nonintegrin
egfp
enhanc
green
fluoresc
protein
fitc
fluorescein
isothiocyan
hpi
hour
post
infect
lsign
liverlymph
nodespecif
intercellular
adhes
integrin
itam
immunoreceptor
tyrosinebas
activ
motif
itim
immunoreceptor
tyrosinebas
inhibitori
motif
merscov
middl
east
respiratori
syndrom
coronaviru
moi
multipl
infect
rtpcr
revers
transcriptasepolymeras
chain
reaction
sarscov
sever
acut
respiratori
syndrom
coronaviru
sarscovpp
ever
acut
respiratori
syndrom
coronaviru
pseudoparticl
tritc
isothiocyan
vsv
vesicular
stomat
viru
author
declar
compet
interest
msi
nhll
phl
hhyl
perform
cell
cultur
molecular
biolog
microscopi
flow
cytometri
studi
cyc
perform
experi
sarscov
lab
mj
msi
nhll
md
jsmp
rb
particip
design
studi
analysi
data
mj
rb
wrote
manuscript
author
comment
approv
final
version
manuscript
